Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems - Full Text View

Sponsor:	Cordis Corporation
Information provided by (Responsible Party):	Cordis Corporation
ClinicalTrials.gov Identifier:	NCT00715884

Purpose

The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.

Condition	Intervention
Coronary Artery Disease Coronary Atherosclerosis	Device: CYPHER® ELITE™ Sirolimus-Eluting Stent System Device: CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment
Official Title:	A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).

Resource links provided by NLM:

MedlinePlus related topics: Atherosclerosis Coronary Artery Disease

Drug Information available for: Sirolimus Everolimus Temsirolimus

U.S. FDA Resources

Further study details as provided by Cordis Corporation:

Primary Outcome Measures:

Percentage of Participants Who Experienced Target Lesion Failure (TLF) [ Time Frame: 12-months post-procedure ] [ Designated as safety issue: Yes ]
The primary endpoint for this study is the percentage of participants who experienced Target Lesion Failure (TLF) during the 12 months post-procedure. A TLF event is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.

Secondary Outcome Measures:

Percentage of Lesion Success [ Time Frame: At procedure ] [ Designated as safety issue: Yes ]
Lesion success is defined as the attainment of < 50 percent residual stenosis (by Quantitative Coronary Angiography (QCA)) using any percutaneous method.
Percentage of Device Success - Protocol Definition [ Time Frame: At procedure ] [ Designated as safety issue: Yes ]
Device success is defined as achievement of a final residual diameter stenosis of <50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. Protocol definition: Only protocol-defined study stents were included.
Percentage of Device Success - All CYPHER® Stents Included [ Time Frame: At procedure ] [ Designated as safety issue: Yes ]
Device success is defined as achievement of a final residual diameter stenosis of <50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. All CYPHER® Stents were included if the final residual stenosis was <50%. Non-study CYPHER® Stents were also included.
Percentage of Participants Who Achieved Procedure Success [ Time Frame: At procedure during hospital stay ] [ Designated as safety issue: Yes ]
Procedure success is defined as achievement of a final diameter stenosis of < 50 percent (by QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion during the hospital stay.
Percentage of Participants Who Experienced Target Lesion Revascularization (TLR) [ Time Frame: 12 months post-procedure ] [ Designated as safety issue: Yes ]
TLR is defined as any "clinically-driven" repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic electrocardiogram (ECG) changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.
Percentage of Participants Who Experienced Target Vessel Revascularization (TVR) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
TVR is defined as any "clinically driven" repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.
Percentage of Participants Who Experienced Target Vessel Failure (TVF) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
Target Vessel failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.
Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
MAJOR ADVERSE CARDIAC EVENTS (MACE) consists of death, myocardial infarction, emergent bypass surgery, and target lesion revascularization.
Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.
Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.
Percentage of Participants Who Experienced Bleeding Complications [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
Bleeding complications include any bleeding events defined by THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI), Global Strategies for Opening Occluded Coronary Arteries (GUSTO), and "Protocol" definitions.
Percentage of Participants Who Died [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
Death incidences include both Cardiac and non-cardiac death.
Percentage of Participants Who Experienced Any Myocardial Infarction (MI) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
Myocardial Infarction includes both Q-wave and WHO Non-Q Wave Myocardial Infarction events.
Percentage of Participants Who Experienced Stroke [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
The stroke definition includes both hemorrhagic and non-hemorrhagic strokes.
Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
Protocol defined Stent thrombosis include both Early and Late Thrombosis. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave MI, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring > 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site-reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.
Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition) [ Time Frame: 12 months post procedure ] [ Designated as safety issue: Yes ]
Academic Research Consortium (ARC) defines STENT THROMBOSIS as consisting of the following:
1. DEFINITE - Angiographic or pathologic confirmation;
2. PROBABLE - Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent;
3. POSSIBLE - Any unexplained death > 30 days.
ARC Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points.
Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition) [ Time Frame: 0-30 days post-procedure ] [ Designated as safety issue: Yes ]
Those ARC stent thromboses occurred between 0 and 30 days post-procedure are early stent thrombosis.
Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition) [ Time Frame: 31-360 days post-procedure ] [ Designated as safety issue: Yes ]
Those ARC stent thromboses occurred between 31 to 360 days post-procedure are late stent thrombosis.

Enrollment:	678
Study Start Date:	July 2008
Estimated Study Completion Date:	June 2015
Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 CYPHER® ELITE™ Sirolimus-Eluting Stent System.	Device: CYPHER® ELITE™ Sirolimus-Eluting Stent System Drug eluting stent Other Name: Cypher ELITE
Active Comparator: 2 CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System	Device: CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System Drug eluting stent Other Name: CYPHER Bx VELOCITY

Detailed Description:

A prospective, single-blind, randomized, multicenter, two arm study. The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects with de novo atherosclerotic CAD in 1 or 2 vessels;
The subject must be >/= 18 years of age;
Female of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment;
Diagnosis of angina pectoris as defined by stable angina pectoris Canadian Cardiovascular Society Classification (Class I, II, III) OR non-ST segment elevation acute coronary syndrome (Braunwald Classification B&C) OR non-ST segment elevation myocardial infarction >/= 48 hours from the time of study index procedure OR asymptomatic subjects with a positive stress test;
Treatment of </= two lesions in one or two major coronary arteries (1 target lesion in each of 2 vessels or 2 target lesions in 1 vessel);
Target vessel diameter must be >/= 2.25mm and </= 4.0 in diameter (visual estimate);
Target lesion stenosis is > 50% and < 100% (visual estimate);
Subject or Legally Authorized Representative must provide written informed consent prior to the procedure using a form that is approved by the Institutional Review Board/Independent Ethics Committee.

Exclusion Criteria:

ST Segment Elevation Myocardial Infarction (STEMI) within 30 days of the study index procedure;
Unprotected left main coronary disease with >/= 50% stenosis;
Total coronary occlusion or TIMI grade 0 or 1 in the target vessel;
Angiographic evidence of thrombus within target lesion(s);
Calcified target lesion(s) which cannot be, in the investigator's opinion, successfully pre-dilated;
Bifurcation disease involving a side branch >/= 2 mm in diameter;
Prior stent within 5 mm of target lesion(s);
Ostial target lesion(s);
Target lesion(s) within a coronary bypass graft (e.g., saphenous vein or arterial graft);
Documented left ventricular ejection fraction </= 25%;
Impaired renal function (creatinine > 250 μmol/L or > 2.5 mg/dl) at the time of treatment;
Pretreatment with devices other than conventional balloon angioplasty;
Significant angulation in the target vessel that, in the Investigator's opinion, may preclude stent delivery and deployment;
Subject previously treated with brachytherapy;
Recipient of heart transplant;
Subject with a life expectancy less than 12 months;
Known allergies to the following: aspirin, clopidogrel bisulfate and ticlopidine, heparin, stainless steel, contrast agent (that cannot be managed medically), or sirolimus that cannot be managed medically;
Any significant medical condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study;
Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints;
In the Investigator's opinion, the lesion is not suitable for stenting;
Known bleeding or hypercoagulable disorder;
Known or suspected active infection at the time of the study procedures;
Subject is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser;
Subject has had major surgical or interventional procedures unrelated to this study within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00715884

Locations

United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010

Sponsors and Collaborators

Cordis Corporation

Investigators

Principal Investigator:

Lowell Satler, MD

Washington Hospital Center

More Information

No publications provided

Responsible Party:	Cordis Corporation
ClinicalTrials.gov Identifier:	NCT00715884 History of Changes
Other Study ID Numbers:	P07-6330
Study First Received:	July 11, 2008
Results First Received:	February 25, 2011
Last Updated:	February 13, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by Cordis Corporation:

Atherosclerosis
de novo native coronary lesion

Additional relevant MeSH terms:

Atherosclerosis
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Sirolimus
Everolimus

Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antifungal Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on May 23, 2012